These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 5325188)

  • 1. Treatment of hyperlipidemia with the ethyl-ester of chlorophenoxyisobutyrate and androsterone.
    Schatz IJ
    Henry Ford Hosp Med J; 1965 Dec; 13(4):447-56. PubMed ID: 5325188
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
    De Gennes JL; Maunand B; Salmon D; Laudat P; Truffert J
    Rev Atheroscler (Paris); 1966; 8(1):27-52. PubMed ID: 5961027
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical experimentation with CPIB (with or without androsterone) in the treatment of hyperlipemia. Apropos of 35 cases].
    Warembourg H; Jaillard J
    Lille Med; 1965 Apr; 10(4):431-6. PubMed ID: 5318637
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-term treatment of previously therapy-resistant cases of primary hypertriglyceridemia of the adult with ethyl-p-chlorophenoxyisobutyrate].
    Braunsteiner H; Herbst M; Sandhofer F; Sailer S
    Dtsch Med Wochenschr; 1967 Dec; 92(50):2302-8. PubMed ID: 6075896
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis].
    Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G
    Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trial with ethyl-a-p-chlorophenoxyisobutyrate (Atromid-S) with special reference to white blood cell counts.
    Engström J
    Acta Med Scand; 1966 Nov; 180(5):519-31. PubMed ID: 5332263
    [No Abstract]   [Full Text] [Related]  

  • 7. [Action of ethyl chlorophenoxyisobutyrate on several types of hyperlipidemia].
    Beaumont V; Swynghedauw B; Beaumont JL; Himbert J
    Rev Atheroscler (Paris); 1966; 8(1):12-20. PubMed ID: 5961026
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical-experimental studies on lipid metabolism using Regelan].
    Hammerl H
    Wien Klin Wochenschr; 1967 Sep; 79(39):720-2. PubMed ID: 4875575
    [No Abstract]   [Full Text] [Related]  

  • 9. [Studies on lipemia in elderly persons and the lipid lowering effect of a clofibrate derivate in 2 groups of test persons].
    Rilliet B; Monnier J
    Praxis; 1969 Jun; 58(25):815-20. PubMed ID: 5819485
    [No Abstract]   [Full Text] [Related]  

  • 10. Divergent effects in the treatment of hyperlipemia.
    Slowe IA; Carter AC; Feldman EB
    Arch Intern Med; 1965 Oct; 116(4):523-30. PubMed ID: 5835355
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypolipidemic agents--newly approved.
    Duncan GG
    Pa Med; 1967 Aug; 70(8):75-6. PubMed ID: 6073724
    [No Abstract]   [Full Text] [Related]  

  • 12. [CPIB: a hypolipidemic agent. Study of 20 patients].
    Verdy M
    Union Med Can; 1966 Sep; 95(9):1049-52. PubMed ID: 5913817
    [No Abstract]   [Full Text] [Related]  

  • 13. [Action mechanism and clinical success of Regelan (Clofibrate)].
    Fitzgerald JD
    Wien Klin Wochenschr; 1967 Sep; 79(39):716-20. PubMed ID: 5595437
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of Atromid on blood lipids in patients with hyperlipemia].
    Baranova LV
    Ter Arkh; 1968 Mar; 40(3):15-20. PubMed ID: 4875984
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of primary hyperlipemias].
    Schlierf G; Kahlke W
    Dtsch Med Wochenschr; 1969 Feb; 94(7):329-32. PubMed ID: 5762992
    [No Abstract]   [Full Text] [Related]  

  • 16. [Action of a 2.2 percent solution of androsterone, in chlorphenisate, on the serum lipoproteins of low density (LDL) in patients resistant to diet therapy].
    Bertolami V; Schneiderman B; Finatti AA; Netto RF
    Arq Bras Cardiol; 1966 Apr; 19(2):111-26. PubMed ID: 5943772
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile-onset diabetes mellitus.
    Danowski TS; Cohn RE; Limaye NR; Novak JF; Saul R; Sunder JH; Moses C
    Clin Pharmacol Ther; 1965; 6(6):716-30. PubMed ID: 5321221
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypolipidemic effect of chlorophenoxyisobutyrate in adult-onset diabetes mellitus.
    Danowski TS; Novak JF; Saul RW; Vester JW; Moses C
    Clin Pharmacol Ther; 1966; 7(5):631-8. PubMed ID: 5957168
    [No Abstract]   [Full Text] [Related]  

  • 19. Observations on the effect of ethyl a-p chlorophenoxyisobutyrate (CPIB) therapy on serum lipid levels and on diabetic and some other retinopathies.
    Vannas S; Esilä R; Tuovinen E
    Acta Ophthalmol (Copenh); 1968; 46(2):162-70. PubMed ID: 5755673
    [No Abstract]   [Full Text] [Related]  

  • 20. Foam cells in the renal glomerulus.
    McKenzie IF; Kincaid-Smith P
    J Pathol; 1969 Jan; 97(1):151-4. PubMed ID: 5783631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.